• Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020

  • Collaborator: Bristol-Myers Squibb

  • Authors: V. Westeel, M. Bourdon, A.B. Cortot, D. Debieuvre, A.C. Toffart, M. Acquadro, B. Arnould, J. Lambert, A. Boisbouvier, L. Radoszycki, O. Wilczynski, F.E. Cotte, A.F. Gaudin, H. Lemasson

Although long-term monitoring of symptoms and HRQoL is associated with survival in cancer patients, HRQoL assessment in clinical practice is suffering from a lack of a standardised approach and from logistical constraints.

Objective: This post-hoc analysis compared patient and clinician perspectives of HRQoL management among cancer patients.